Monopar (MNPR) Acting CMO Patrice Rioux Exercises Options

What Happened Patrice Rioux, Acting Chief Medical Officer of Monopar Therapeutics (MNPR), exercised stock-derived awards on August 26, 2026 to acquire 2,760 shares of common stock (two derivative/option transactions of 1,380 shares each). One exercise was at $0.01 per share (1,380 shares; total cash cost $7) and the other reported at $0.00 (1,380 shares; $0). On the same day Rioux sold 1 share in an open-market transaction for $111.26 (proceeds reported as $111). The exercises are acquisitions (not sales), while the single-share sale was a routine disposition.

Key Details

• Transaction date: August 26, 2026; Form 4 filed August 27, 2026 (timely filing).
• Exercises/acquisitions: 1,380 shares @ $0.01 (total $7) and 1,380 shares @ $0.00 (total $0) — 2,760 shares acquired in total.
• Sale: 1 share sold @ $111.26 (proceeds $111).
• Shares owned after transaction: not specified in this filing.
• Footnotes: F1 — the sale was effected pursuant to a Rule 10b5-1 trading plan executed May 27, 2026. F2 — the exercised options trace to a December 15, 2016 grant with vesting that occurred in early-mid 2017.
• Filing timeliness: Report appears timely (filed the business day after the transactions).

Context These transactions involved option/derivative exercises (reporting code M) rather than open-market purchases. Exercising vested options at a nominal strike is a common way insiders acquire shares; it does not by itself indicate a change in sentiment. The single-share sale was executed under a 10b5-1 plan, a pre-established trading arrangement that prespecifies sales and helps avoid concerns about trading on material nonpublic information.